U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H27Cl2N3O2
Molecular Weight 448.3861
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARIPIPRAZOLE

SMILES

C(CCOc1ccc2CCC(=Nc2c1)O)CN3CCN(CC3)c4cccc(c4Cl)Cl

InChI

InChIKey=CEUORZQYGODEFX-UHFFFAOYSA-N
InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)

HIDE SMILES / InChI

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/12784105/, https://www.ncbi.nlm.nih.gov/pubmed/12587943, https://www.ncbi.nlm.nih.gov/pubmedhealth/PMHT0000157/

Aripiprazole is the first next-generation atypical antipsychotic. The unique actions of aripiprazole in humans are likely a combination of "functionally selective" activation of D(2) (and possibly D(3))-dopamine receptors and serotonin 5-HT(1A) receptors, coupled with inhibition of 5-HT(2A) receptors. Aripiprazole was approved by FDA (Abilify trade name) for the treatment of schizophrenia; manic and mixed episodes associated with bipolar I disorder; major depressive disorder; irritability associated with autistic disorder; Tourette’s disorder and agitation associated with schizophrenia or bipolar mania.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

1.03731842E12
Primary
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

1.03731842E12
Primary
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

1.03731842E12
Primary
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

1.03731842E12
Primary
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic. The oral formulations are indicated for: Schizophrenia, Acute Treatment of Manic and Mixed Episodes associated with Bipolar I, Adjunctive Treatment of Major Depressive Disorder, Irritability Associated with Autistic Disorder, Treatment of Tourette’s disorder, The injection is indicated for: Agitation associated with schizophrenia or bipolar mania

Launch Date

1.03731842E12
Primary
ABILIFY

Approved Use

ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder, both as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in one maintenance monotherapy trial and in one maintenance adjunctive trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5) 1.1 Schizophrenia ABILIFY is indicated for the treatment of schizophrenia. The efficacy of ABILIFY was established in four 4-6 week trials in adults and one 6-week trial in adolescents (13 to 17 years). Maintenance efficacy was demonstrated in one trial in adults and can be extrapolated to adolescents [see CLINICAL STUDIES (14.1)

Launch Date

1.03731842E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
163 ng/mL
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARIPIPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2947 ng × h/mL
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARIPIPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
52.9 h
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARIPIPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
10 mg 1 times / day multiple, oral
dose: 10 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered:
ARIPIPRAZOLE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 10-17 years
n = 6
Health Status: unhealthy
Condition: Psychiatric Disorders
Age Group: 10-17 years
Sex: M+F
Population Size: 6
Sources:
Other AEs: Abdominal pain upper, Vomiting...
Other AEs:
Abdominal pain upper (17%)
Vomiting (17%)
Dizziness (17%)
Headache (50%)
Sedation (33%)
Somnolence (17%)
Sources:
2 mg single, intravenous
Dose: 2 mg
Route: intravenous
Route: single
Dose: 2 mg
Sources:
healthy, 35 years (range: 18-45 years)
n = 16
Health Status: healthy
Age Group: 35 years (range: 18-45 years)
Sex: M+F
Population Size: 16
Sources:
45 mg single, intramuscular
Highest studied dose
Dose: 45 mg
Route: intramuscular
Route: single
Dose: 45 mg
Sources:
unhealthy, 39 years (range: 18-65 years)
n = 4
Health Status: unhealthy
Condition: schizophrenia
Age Group: 39 years (range: 18-65 years)
Sex: M+F
Population Size: 4
Sources:
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Other AEs: Vomiting, Somnolence...
Other AEs:
Vomiting
Somnolence
Tremor
Acidosis
Aggression
Aspartate aminotransferase increased
Atrial fibrillation
Coma
Confusional state
Convulsion
Blood creatine phosphokinase increased
Depressed level of consciousness
Hypertension
Hypokalemia
Hypotension
Lethargy
Loss of consciousness
QT prolonged
Aspiration pneumonia
Respiratory arrest
Status epilepticus
Tachycardia
Sources:
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Other AEs: Extrapyramidal disorder, Neuroleptic malignant syndrome...
Other AEs:
Extrapyramidal disorder (serious, 1 patient)
Neuroleptic malignant syndrome (serious, 1 patient)
Aggression (serious, 1 patient)
Schizophrenia (serious, 1 patient)
Nausea (below serious, 9 patients)
Nasopharyngitis (below serious, 5 patients)
Dizziness (below serious, 7 patients)
Extrapyramidal disorder (below serious, 13 patients)
Headache (below serious, 16 patients)
Somnolence (below serious, 11 patient)
Sources:
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Other AEs: Varicella, Depression...
Other AEs:
Varicella (serious, 1 patient)
Depression (serious, 1 patient)
Schizophrenia (serious, 1 patient)
Suicidal ideation (serious, 1 patient)
Thrombophlebitis (serious, 1 patient)
Nausea (below serious, 10 patients)
Nasopharyngitis (below serious, 5 patients)
Dizziness (below serious, 4 patients)
Extrapyramidal disorder (below serious, 22 patients)
Headache (below serious, 11 patient)
Somnolence (below serious, 22 patients)
Tremor (below serious, 12 patients)
Sources:
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Other AEs: Vomiting, Somnolence...
Other AEs:
Vomiting
Somnolence
Tremor
Acidosis
Aggression
Aspartate aminotransferase increased
Atrial fibrillation
Coma
Confusional state
Convulsion
Blood creatine phosphokinase increased
Depressed level of consciousness
Hypertension
Hypokalemia
Hypotension
Lethargy
Loss of consciousness
QT prolonged
Aspiration pneumonia
Respiratory arrest
Status epilepticus
Tachycardia
Sources:
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: adult
Sources:
Other AEs: Adverse event...
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Other AEs: Constipation, Diarrhea...
Other AEs:
Constipation (below serious, 8 patients)
Diarrhea (below serious, 7 patients)
Nausea (below serious, 2 patients)
Abdominal discomfort (below serious, 7 patients)
Vomiting (below serious, 15 patients)
Decreased appetite (below serious, 12 patients)
Increased appetite (below serious, 16 patients)
Drowsiness (below serious, 5 patients)
Tiredness (below serious, 21 patient)
Fever (below serious, 3 patients)
Weight gain (below serious, 8 patients)
Muscle rigidity (below serious, 3 patients)
Tremor (below serious, 3 patients)
Nervousness (below serious, 3 patients)
Repetitive speech (below serious, 3 patients)
Restlessness (below serious, 3 patients)
Feeling sad (below serious, 3 patients)
Self injurious behavior (below serious, 3 patients)
Enuresis (below serious, 3 patients)
Dizziness (below serious, 4 patients)
Nose bleed (below serious, 3 patients)
Sources:
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Other AEs: Abdominal pain, Bruising...
Other AEs:
Abdominal pain (below serious, 7 patients)
Bruising (below serious, 2 patients)
Constipation (below serious, 6 patients)
Diarrhea (below serious, 9 patients)
Dizziness (below serious, 5 patients)
Dry mouth (below serious, 6 patients)
Enuresis (below serious, 5 patients)
Headache (below serious, 6 patients)
Insomnia (below serious, 8 patients)
Malaise (below serious, 7 patients)
Mucosal ulceration (below serious, 4 patients)
Nausea (below serious, 10 patients)
Restlessness (below serious, 5 patients)
Sedation (below serious, 7 patients)
Tinnitus (below serious, 7 patients)
Tremor (below serious, 8 patients)
Vomiting (below serious, 10 patients)
Weight loss (below serious, 4 patients)
Sources:
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Other AEs: Restlessness, Decreased activity...
Other AEs:
Restlessness (below serious, 2 patients)
Decreased activity (below serious, 1 patient)
Drowsiness (below serious, 2 patients)
Vertigo (below serious, 1 patient)
Cold extremities (below serious, 1 patient)
Blurred vision (below serious, 2 patients)
Sexual disorder NOS (below serious, 2 patients)
Joint stiffness (below serious, 1 patient)
Sources:
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Other AEs: Rhabdomyolysis, Pneumonia...
Other AEs:
Rhabdomyolysis (serious, 1 patient)
Pneumonia (serious, 1 patient)
Cellulitis (serious, 1 patient)
Abrasions (below serious, 3 patients)
Akathisia (below serious, 12 patients)
Drowsiness (below serious, 6 patients)
Fatigue (below serious, 8 patients)
Depressed mood (below serious, 3 patients)
Hypernatremia (below serious, 4 patients)
Hypocalcemia (below serious, 3 patients)
ALT increased (below serious, 8 patients)
Aspartate aminotransferase increased (below serious, 6 patients)
Restlessness (below serious, 4 patients)
Sleep disturbance (below serious, 3 patients)
Infection upper respiratory (below serious, 6 patients)
Sources:
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Other AEs: Suicidal ideation, Gun shot wound...
Other AEs:
Suicidal ideation (serious, 2 patients)
Gun shot wound (serious, 1 patient)
Injury (serious, 1 patient)
Multiple injuries (serious, 1 patient)
Diabetes mellitus (serious, 1 patient)
Hyperglycaemia (serious, 1 patient)
Pancreatic carcinoma (serious, 1 patient)
Hallucination, auditory (serious, 1 patient)
Suicide attempt (serious, 1 patient)
Headache (below serious, 16 patients)
Insomnia (below serious, 27 patients)
Tremor (below serious, 16 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Abdominal pain upper 17%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 10-17 years
n = 6
Health Status: unhealthy
Condition: Psychiatric Disorders
Age Group: 10-17 years
Sex: M+F
Population Size: 6
Sources:
Dizziness 17%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 10-17 years
n = 6
Health Status: unhealthy
Condition: Psychiatric Disorders
Age Group: 10-17 years
Sex: M+F
Population Size: 6
Sources:
Somnolence 17%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 10-17 years
n = 6
Health Status: unhealthy
Condition: Psychiatric Disorders
Age Group: 10-17 years
Sex: M+F
Population Size: 6
Sources:
Vomiting 17%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 10-17 years
n = 6
Health Status: unhealthy
Condition: Psychiatric Disorders
Age Group: 10-17 years
Sex: M+F
Population Size: 6
Sources:
Sedation 33%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 10-17 years
n = 6
Health Status: unhealthy
Condition: Psychiatric Disorders
Age Group: 10-17 years
Sex: M+F
Population Size: 6
Sources:
Headache 50%
30 mg 1 times / day multiple, oral
Highest studied dose
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources:
unhealthy, 10-17 years
n = 6
Health Status: unhealthy
Condition: Psychiatric Disorders
Age Group: 10-17 years
Sex: M+F
Population Size: 6
Sources:
Acidosis
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Aggression
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Aspartate aminotransferase increased
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Aspiration pneumonia
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Atrial fibrillation
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Blood creatine phosphokinase increased
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Coma
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Confusional state
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Convulsion
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Depressed level of consciousness
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Hypertension
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Hypokalemia
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Hypotension
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Lethargy
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Loss of consciousness
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
QT prolonged
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Respiratory arrest
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Somnolence
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Status epilepticus
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Tachycardia
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Tremor
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Vomiting
195 mg single, oral
Overdose
Dose: 195 mg
Route: oral
Route: single
Dose: 195 mg
Sources:
unhealthy, < 12 years
n = 10
Health Status: unhealthy
Age Group: < 12 years
Population Size: 10
Sources:
Somnolence below serious, 11 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Extrapyramidal disorder below serious, 13 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Headache below serious, 16 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Nasopharyngitis below serious, 5 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Dizziness below serious, 7 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Nausea below serious, 9 patients
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Aggression serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Extrapyramidal disorder serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Neuroleptic malignant syndrome serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Schizophrenia serious, 1 patient
10 mg 1 times / day steady, oral
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 100
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 100
Sources:
Nausea below serious, 10 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Headache below serious, 11 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Tremor below serious, 12 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Extrapyramidal disorder below serious, 22 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Somnolence below serious, 22 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Dizziness below serious, 4 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Nasopharyngitis below serious, 5 patients
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Depression serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Schizophrenia serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Suicidal ideation serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Thrombophlebitis serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Varicella serious, 1 patient
30 mg 1 times / day steady, oral
Dose: 30 mg, 1 times / day
Route: oral
Route: steady
Dose: 30 mg, 1 times / day
Sources:
unhealthy, adolescent
n = 102
Health Status: unhealthy
Condition: schizophrenia
Age Group: adolescent
Population Size: 102
Sources:
Acidosis
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Aggression
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Aspartate aminotransferase increased
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Aspiration pneumonia
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Atrial fibrillation
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Blood creatine phosphokinase increased
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Coma
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Confusional state
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Convulsion
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Depressed level of consciousness
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Hypertension
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Hypokalemia
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Hypotension
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Lethargy
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Loss of consciousness
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
QT prolonged
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Respiratory arrest
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Somnolence
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Status epilepticus
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Tachycardia
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Tremor
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Vomiting
1080 mg single, oral
Overdose
Dose: 1080 mg
Route: oral
Route: single
Dose: 1080 mg
Sources:
unhealthy, adult
n = 1
Health Status: unhealthy
Age Group: adult
Population Size: 1
Sources:
Adverse event grade 5
10 mg 1 times / day steady, oral
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: steady
Dose: 10 mg, 1 times / day
Sources:
unhealthy, adult
Health Status: unhealthy
Condition: Dementia-Related Psychosis
Age Group: adult
Sources:
Decreased appetite below serious, 12 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Vomiting below serious, 15 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Increased appetite below serious, 16 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Nausea below serious, 2 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Tiredness below serious, 21 patient
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Enuresis below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Feeling sad below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Fever below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Muscle rigidity below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Nervousness below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Nose bleed below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Repetitive speech below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Restlessness below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Self injurious behavior below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Tremor below serious, 3 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Dizziness below serious, 4 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Drowsiness below serious, 5 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Abdominal discomfort below serious, 7 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Diarrhea below serious, 7 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Constipation below serious, 8 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Weight gain below serious, 8 patients
15 mg 1 times / day steady, oral (max)
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy, children
n = 40
Health Status: unhealthy
Condition: autism
Age Group: children
Population Size: 40
Sources:
Nausea below serious, 10 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Vomiting below serious, 10 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Bruising below serious, 2 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Mucosal ulceration below serious, 4 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Weight loss below serious, 4 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Dizziness below serious, 5 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Enuresis below serious, 5 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Restlessness below serious, 5 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Constipation below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Dry mouth below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Headache below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Abdominal pain below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Malaise below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Sedation below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Tinnitus below serious, 7 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Insomnia below serious, 8 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Tremor below serious, 8 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Diarrhea below serious, 9 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 20
Health Status: unhealthy
Condition: schizophrenia
Sex: F
Population Size: 20
Sources:
Cold extremities below serious, 1 patient
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Decreased activity below serious, 1 patient
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Joint stiffness below serious, 1 patient
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Vertigo below serious, 1 patient
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Blurred vision below serious, 2 patients
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Drowsiness below serious, 2 patients
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Restlessness below serious, 2 patients
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Sexual disorder NOS below serious, 2 patients
20 mg 1 times / day steady, oral (max)
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 7
Health Status: unhealthy
Condition: posttraumatic stress disorder
Population Size: 7
Sources:
Akathisia below serious, 12 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Abrasions below serious, 3 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Depressed mood below serious, 3 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Hypocalcemia below serious, 3 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Sleep disturbance below serious, 3 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Hypernatremia below serious, 4 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Restlessness below serious, 4 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Aspartate aminotransferase increased below serious, 6 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Drowsiness below serious, 6 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Infection upper respiratory below serious, 6 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
ALT increased below serious, 8 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Fatigue below serious, 8 patients
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Cellulitis serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Pneumonia serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Rhabdomyolysis serious, 1 patient
20 mg 1 times / day steady, oral
Dose: 20 mg, 1 times / day
Route: oral
Route: steady
Dose: 20 mg, 1 times / day
Sources:
unhealthy
n = 45
Health Status: unhealthy
Condition: Methamphetamine Dependence
Population Size: 45
Sources:
Headache below serious, 16 patients
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Tremor below serious, 16 patients
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Insomnia below serious, 27 patients
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Diabetes mellitus serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Gun shot wound serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Hallucination, auditory serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Hyperglycaemia serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Injury serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Multiple injuries serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Pancreatic carcinoma serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Suicide attempt serious, 1 patient
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
Suicidal ideation serious, 2 patients
400 mg 1 times / 4 weeks steady, oral
Dose: 400 mg, 1 times / 4 weeks
Route: oral
Route: steady
Dose: 400 mg, 1 times / 4 weeks
Sources:
unhealthy
n = 269
Health Status: unhealthy
Condition: schizophrenia
Population Size: 269
Sources:
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
not significant
unlikely (co-administration study)
Comment: aripiprazole had no effect ont the PK of omeprazole
Page: 43.0
not significant
unlikely (co-administration study)
Comment: aripiprazole had no effect on the PK of warfarin
Page: 43.0
not significant
unlikely (co-administration study)
Comment: aripiprazole had no effect on the PK of of dextromethorphan
Page: 43.0
not significant
unlikely (co-administration study)
Comment: aripiprazole had no effect on the PK of of dextromethorphan
Page: 43.0
not significant
yes [IC50 1.2 uM]
yes [IC50 3.5 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
yes
yes
yes (co-administration study)
Comment: Coadministration of aripiprazole with quinidine, a potent inhibitor of CYP2D6, increased the AUC of aripiprazole by 112% but decreased the AUC of its active metabolite, dehydroaripiprazole, by 35%; PHARMACOGENOMIC STUDY: 82% increase in aripiprazole systemic exposure in CYP2D6 PM compared to EM, net increase of aripiprazole exposure is greater than 60%, total body clearance of aripiprazole in PM decreased by 40%, not adequately studied in PM patients;
Page: 29.0
yes
yes (co-administration study)
Comment: Coadministration of ketoconazole increased the AUC of aripiprazole and its active metabolite by 63% and 77%, respectively; Coadministration of carbamazepine, a potent CYP3A4 inducer, resulted in an approximate 70% decrease in Cmax and AUC values of both aripiprazole and its active metabolite, dehydro-aripiprazole;
Page: 29.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
The psychopharmacology of ziprasidone: receptor-binding properties and real-world psychiatric practice.
2003
Similarities and differences among antipsychotics.
2003
Choice of maintenance medication for schizophrenia.
2003
[The next generation of "atypical" antipsychotics: the role of positron emission tomography].
2003 Aug
Aripiprazole-induced improvement in tardive dyskinesia.
2003 Dec
Medication developments in the treatment of mental illness.
2003 Dec
Relationship of atypical antipsychotics with development of diabetes mellitus.
2003 Dec
Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia.
2003 Dec
Aripiprazole.
2003 Dec 1
Antipsychotic medication and seizures: a review.
2003 Jul
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
2003 Jul
Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone.
2003 Jul 4
Aripiprazole and extrapyramidal symptoms.
2003 Nov
Aripiprazole in an adult with Asperger disorder.
2003 Nov
Serotonin receptors: their key role in drugs to treat schizophrenia.
2003 Oct
Mechanism of new antipsychotic medications: occupancy is not just antagonism.
2003 Oct
Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study.
2003 Sep
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.
2003 Sep
Aripiprazole: in acute mania associated with bipolar I disorder.
2004
Dopamine partial agonists: a new class of antipsychotic.
2004
Focus on aripiprazole.
2004
Using antipsychotic agents in older patients.
2004
Weight gain associated with atypical antipsychotic use in children and adolescents: prevalence, clinical relevance, and management.
2004
Dose response and dose equivalence of antipsychotics.
2004 Apr
Gateways to clinical trials.
2004 Apr
The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update.
2004 Apr
Excessive somnolence from aripiprazole in a child.
2004 Apr
The novel antipsychotic aripiprazole is a partial agonist at short and long isoforms of D2 receptors linked to the regulation of adenylyl cyclase activity and prolactin release.
2004 Apr 2
Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns.
2004 Apr 27
Aripiprazole, a novel atypical antipsychotic drug.
2004 Feb
Naturalistic studies of second generation antipsychotics in the treatment of schizophrenia.
2004 Feb
A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation.
2004 Feb
Pharmacogenomic-guided rational therapeutic drug monitoring: conceptual framework and application platforms for atypical antipsychotics.
2004 Feb
Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions.
2004 Feb
Schizophrenia: from dopamine to glutamate and back.
2004 Feb
Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder.
2004 Feb
Aripiprazole and Parkinson's disease psychosis.
2004 Feb
Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers.
2004 Feb
Selection of atypical antipsychotics for the management of schizophrenia.
2004 Feb
Aripiprazole possibly worsens psychosis.
2004 Jan
Worsened agitation with aripiprazole: adverse effect of dopamine partial agonism?
2004 Jan
In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function.
2004 Jan 1
Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience.
2004 Jan-Feb
Gateways to clinical trials.
2004 Jan-Feb
The case for atypical antipsychotics in bipolar disorder.
2004 Jan-Mar
Clinical utilization of atypical antipsychotics in pregnancy and lactation.
2004 Jul-Aug
Evidence-based pharmacotherapy of schizophrenia.
2004 Jun
Aripiprazole, a novel antipsychotic drug, preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain.
2004 Jun 16
Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability.
2004 May
Aripiprazole is effective for relapse prevention in people with chronic stable schizophrenia.
2004 May
Patents

Sample Use Guides

In adults with schizophrenia the recommended starting and target dose for aripiprazole (ABILIFY) is 10 or 15 mg/day. In adolescents the target dose is 10 mg/day. In adults with Bipolar I Disorder, the recommended starting dose is 15 mg given once daily as monotherapy and 10 mg to 15 mg given once daily as adjunctive therapy with lithium or valproate. In pediatric patients (10 to 17 years) with Bipolar I Disorder, the starting dose as monotherapy is 2 mg/day, with titration to 5 mg/day after 2 days, and a target dose of 10 mg/day after 2 additional days. In adults with Major Depressive Disorder, the recommended starting dose as adjunctive treatment for patients already taking an antidepressant is 2 to 5 mg/day. The recommended dosage range is 2 to 15 mg/day. In pediatric patients with Irritability Associated with Autistic Disorder, dosing should be initiated at 2 mg/day. The dose should be increased to 5 mg/day, with subsequent increases to 10 or 15 mg/day if needed. In pediatric patient with Tourette’s Disorder, the recommended dosage is 5 to 20 mg/day. In adults with Agitation Associated with Schizophrenia or Bipolar Mania, the recommended dose is 9.75 mg. The recommended dosage range is 5.25 to 15 mg.
Route of Administration: Other
PC12 cells were treated with 0.001-1.0 uM aripiprazole in the presence of NGF (2.5ng/ml). Aripiprazole significantly potentiated nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells, in a concentration-dependent manner.
Name Type Language
ARIPIPRAZOLE
EMA EPAR   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
ARIPIPRAZOLE [USAN]
Common Name English
ARIPIPRAZOLE [USP MONOGRAPH]
Common Name English
ABILIFY MYCITE
Brand Name English
ABILIFY MAINTENA
Brand Name English
OPC-14597
Code English
ARIPIPRAZOLE [MART.]
Common Name English
ARIPIPRAZOLE [HSDB]
Common Name English
OPC-31
Code English
ARIPIPRAZOLE [INN]
Common Name English
2(1H)-QUINOLINONE, 7-(4-(4-(2,3-DICHLOROPHENYL)-1-PIPERAZINYL)BUTOXY)-3,4-DIHYDRO-
Systematic Name English
ARIPIPREX
Brand Name English
7-(4-(4-(2,3-DICHLOROPHENYL)-1-PIPERAZINYL)BUTOXY)-3,4-DIHYDROCARBOSTYRIL
Common Name English
NSC-759266
Code English
ARIPIPRAZOLE [WHO-DD]
Common Name English
ARIPIPRAZOLE [MI]
Common Name English
ARIPIPRAZOLE [VANDF]
Common Name English
ARIPIPRAZOLE [JAN]
Common Name English
ARIPIPRAZOLE [EMA EPAR]
Common Name English
ABILIFY
Brand Name English
ARIPIPRAZOLE [USP-RS]
Common Name English
ARIPIPRAZOLE [EP MONOGRAPH]
Common Name English
ARIPIPRAZOLE [ORANGE BOOK]
Common Name English
ABILIFY MYCITE KIT
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C29710
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
FDA ORPHAN DRUG 207905
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
EMA ASSESSMENT REPORTS ABILIFY (AUTHORIZED: BIPOLAR DISORDER)
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
LIVERTOX 62
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
EMA ASSESSMENT REPORTS ABILIFY MAINTENA (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
WHO-ATC N05AX12
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
FDA ORPHAN DRUG 694219
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
EMA ASSESSMENT REPORTS ABILIFY (AUTHORIZED: SCHIZOPHRENIA)
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
WHO-VATC QN05AX12
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
NDF-RT N0000175430
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
Code System Code Type Description
HSDB
7320
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
USP_CATALOG
1042634
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
ARIPIPRAZOLE
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
LACTMED
Aripiprazole
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
MERCK INDEX
M2046
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY Merck Index
INN
7477
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
PUBCHEM
60795
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
EPA CompTox
129722-12-9
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
NCI_THESAURUS
C47403
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
DRUG BANK
DB01238
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
IUPHAR
34
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
ChEMBL
CHEMBL1112
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
EVMPD
SUB05564MIG
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
DRUG CENTRAL
242
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
MESH
C094645
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
FDA UNII
82VFR53I78
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY
RXCUI
89013
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY RxNorm
CAS
129722-12-9
Created by admin on Fri Jun 25 21:06:44 UTC 2021 , Edited by admin on Fri Jun 25 21:06:44 UTC 2021
PRIMARY